Trafficking of activated lymphocytes into the RENCA tumour microcirculation in vivo in mice

British Journal of Cancer

Volumn 76, Issue 12, 1997, Pages 1572-1578

  Brown, N J ^a   Ali, S ^b   Reed, M W R ^a   Wiltrout, R ^c   Rees, R C ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immunotherapy; Leucocyte lymphocyte trafficking; RENCA tumour; Tumour microcirculation

Indexed keywords

FLUORESCENT DYE; INTERLEUKIN 2;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; CREMASTER MUSCLE; EFFECTOR CELL; INTERSTITIUM; KIDNEY CARCINOMA; LYMPHOCYTE ACTIVATION; MICROCIRCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR CELL LINE; TUMOR VASCULARIZATION;

EID: 0030719455     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.599     Document Type: Article

References (27)

1. Baez J (1973) An open cremaster preparation for the study of blood vessels by in-vivo microscopy. Microvasc Res 5: 384-395
2. 51Cr as cell labels investigations of tumour cell migration. Nucl Med Biol 17: 781-791
3. Basse PH, Nanmark U, Johansson BR, Herberman RB and Goldfarb RH (1991) Establishment of cell-to-cell contacts by adoptively transferred adherent lymphokine activated killer cells with metastatic melanoma cells. J Natl Cancer Inst 83: 944-950
4. Basse P, Herberman RB, Hokland M and Goldfarb RH (1992) Tissue distribution of adoptively transferred adherent lymphokine-activated killer cells assessed by different cell labels. Cancer Immunol Immunother 34: 221-227
5. Bassil B, Dosoretz DE and Prout Jr GR (1985) Validation of the tumour, nodes and metastasis classification of renal cell carcinoma. J Urol 134: 450-454
6. Bergers J, Otter W, Dullens H, Groot J, Steerenberg P, Filius P and Crommelin J (1994) Effect of immunomodulators on specific tumour immunity induced by liposome-encapsulated tumour associated antigens. Int J Cancer 56: 721-726
7. Brown NJ and Reed MWR (1997) Leucocyte interactions with the mouse cremaster muscle microcirculation in vivo in response to tumour conditioned medium. Br J Cancer 75: 993-999
8. Ettinghausen SE, Lipford EH, Mule JJ and Rosenberg SA (1985) Recombinant interleukin-2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. J Immunol 135: 3623-3628
9. Ettinghausen SE and Rosenberg SA (1986) Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimisation of the schedule and route of administration of recombinant interleukin-2. Cancer Res 46: 2784-2789
10. Fukumura D, Salehi HA, Witwer B, Tuma RF, Melder RJ and Jain RK (1995) Tumour necrosis factor induced leucocyte adhesion in normal and tumour vessels: effect of tumour type, transplantation site and host strain. Cancer Res 55: 4824-4829
11. Garbett EA, Reed MWR and Brown NJ (1994) Viability and visualisation of fluorescently labelled lymphocytes in vitro and in vivo. Int J Micro Clin Exp 14: 249
12. Hayatt K, Rodgers S, Bruce L, Rees RC, Chapman K, Reeder S, Dorren MS, Sheridan E, Sreenivasan T and Hancock BW (1991) Malignant melanoma and renal cell carcinoma: Immunological and haematological effects of recombinant interleukin 2. Eur J Cancer 27: 1009-1014
13. Jain RK (1988) Determinants of blood flow: A review. Cancer Res 48: 2641-2658
14. Lafreniere R and Rosenberg SA (1988) Successful immunotherapy of murine experimental hepatic metastases with lymphokine activated killer cells and recombinant interleukin-2. Cancer Res 45: 3735-3741
15. Ley K, Bullard DC, Arbones ML, Bosse R, Vestweber D, Tedder TF and Beaudet AL (1995) Sequential contribution of L-and P-selectin to leucocyte rolling in vivo. J Exp Med 181: 669-675
16. Melder RJ, Walker ER, Herberman RB and Whiteside TL (1990) Surface characteristics, morphology and ultrastructure of human adherent lymphokine-activated killer (A-LAK) cells. J Leukocyte Biol 48: 163-173
17. Melder RJ, Salehi HA and Jain RK (1995) Interaction of activated natural killer cells with normal and tumour vessels in cranial windows in mice. Microvasc Res 50: 35-44
18. Murphy GP and Hruskesky WJ (1980) A murine renal cell carcinoma. J Natl Cancer Inst 50: 1013-1015
19. Palmer PA, Vinke J, Evens P, Pourreau C, Oskram R, Roest G, Vlems F, Becker L, Loriaux E and Franks CR (1992) Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells or the treatment of advanced renal cell carcinoma. Eur J Cancer 28A: 1038-1044
20. Reed MWR, Weiman TJ, Shuschke DA, Tseng MT and Miller FN (1989) A comparison of the effects of photodynamic therapy on normal tumour vessels in the rat microcirculation. Radiat Res 119: 542-552
21. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan LM, Robertson CN, Lee RE, Rubin JT, Sepp CA, Simpson CG and White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or interleukin-2 alone. N Engl J Med 316: 889-897
22. Rosenberg SA, Packard BS and Aebersold PM (1988) Use of tumour infiltrating lymphocytes and IL2 in immunotherapy of patients with metastatic melanoma. N Engl J Med 319: 1676-1680
23. Sasaki A, Jain RK, Maghazachi AA, Goldfarb RH and Herberman RB (1984) Low deformability of lymphokine activated killer cells as a possible determinant of in vivo distribution. Cancer Res 49: 3742-3746
24. Sasaki A, Melder RJ, Whiteside TL, Herberman RB and Jain RK (1991) Preferential localisation of human adherent lymphokine-activated killer cells in tumour microcirculation. J Natl Cancer Inst 83: 433-437
25. Schwarz RE, Vujanovic NL and Hiserodt JC (1989) Enhanced antimetastatic activity of lymphokine activated killer cells purified and expanded by their adherence to plastic. Cancer Res 49: 1441-1446
26. 51chromium as cell labels. Cancer Immunol Immunother 14: 172-174
27. NZ Klitzman B, Dodge R and Dewhirst MW (1992) Diminished leukocyte-endothelium interaction with tumor microvessels. Cancer Res 52: 4265-4268